Literature DB >> 17145596

The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma.

Tomás Alvaro1, Marylène Lejeune, Francisca I Camacho, Ma Teresa Salvadó, Lydia Sánchez, Juan F García, Carlos Lopez, Joaquín Jaén, Ramón Bosch, Lluis E Pons, Carmen Bellas, Miguel A Piris.   

Abstract

BACKGROUND AND OBJECTIVES: The presence of tumor-associated macrophages (TAM) is a prognostic factor for survival in follicular lymphoma (FL). Overexpression and/or activation of the signal transducer and activator of transcription 1 (STAT1) in these TAM have also been observed. The aim of this study was to determine the extent to which macrophages are present in FL and to investigate the expression of STAT1 in these cells. DESIGN AND METHODS: We retrospectively analyzed 211 patients with distinct stages and grades of FL. Expression of the CD68 proteins, chosen as a marker for macrophages, and STAT1 was quantified by immunohistochemistry and double immunofluorescence.
RESULTS: Automated determinations revealed the presence of CD68-positive macrophages in all FL tissues studied (mean 57.6+/-45.1 cells/field), while STAT1 protein was expressed in 29.94% of cases. Double-fluorescence staining confirmed that STAT1 protein co-localized exclusively with CD68, indicating the presence of a subset of STAT1-expressing TAM localized principally in the vicinity of tumor cells. Multivariate analysis showed that, besides the Follicular Lymphoma International Prognostic Index (FLIPI) classification, expression of STAT1 was an important independent prognostic factor for shorter overall survival in FL. INTERPRETATION AND
CONCLUSIONS: These results demonstrate the presence of STAT1-expressing TAM in FL and their association with an adverse outcome, thus emphasizing the relevance of non-tumor cells in the control of the growth and survival of lymphoma cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17145596

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  32 in total

1.  Automated quantification of nuclear immunohistochemical markers with different complexity.

Authors:  Carlos López; Marylène Lejeune; María Teresa Salvadó; Patricia Escrivà; Ramón Bosch; Lluis E Pons; Tomás Alvaro; Jordi Roig; Xavier Cugat; Jordi Baucells; Joaquín Jaén
Journal:  Histochem Cell Biol       Date:  2008-01-03       Impact factor: 4.304

2.  Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma.

Authors:  Marylène Lejeune; Tomás Alvaro
Journal:  Haematologica       Date:  2009-01       Impact factor: 9.941

3.  Effects of image compression on automatic count of immunohistochemically stained nuclei in digital images.

Authors:  Carlos López; Marylène Lejeune; Patricia Escrivà; Ramón Bosch; Maria Teresa Salvadó; Lluis E Pons; Jordi Baucells; Xavier Cugat; Tomás Alvaro; Joaquín Jaén
Journal:  J Am Med Inform Assoc       Date:  2008-08-28       Impact factor: 4.497

4.  Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure.

Authors:  Marylène Lejeune; Joaquín Jaén; Lluis Pons; Carlos López; Maria-Teresa Salvadó; Ramón Bosch; Marcial García; Patricia Escrivà; Jordi Baucells; Xavier Cugat; Tomás Alvaro
Journal:  J Anat       Date:  2008-06       Impact factor: 2.610

5.  Assessing the prognostic impact of immune cell infiltrates in follicular lymphoma.

Authors:  Falko Fend; Leticia Quintanilla-Martínez
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

6.  Immunotherapy with rituximab in follicular lymphomas.

Authors:  Carmen Saguna; Ileana Delia Mut; Anca Roxana Lupu; Mihaela Tevet; Horia Bumbea; Cornel Dragan
Journal:  Maedica (Buchar)       Date:  2011-04

Review 7.  Pathogenesis of follicular lymphoma.

Authors:  Robert Kridel; Laurie H Sehn; Randy D Gascoyne
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

8.  EBV infection determines the immune hallmarks of plasmablastic lymphoma.

Authors:  Pauline Gravelle; Sarah Péricart; Marie Tosolini; Bettina Fabiani; Paul Coppo; Nadia Amara; Alexandra Traverse-Gléhen; Nathalie Van Acker; Pierre Brousset; Jean-Jacques Fournie; Camille Laurent
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

Review 9.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

Review 10.  The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma.

Authors:  Leanne C Huysentruyt; Michael S McGrath
Journal:  J Leukoc Biol       Date:  2009-12-30       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.